Tuesday, August 7, 2012

Medial Medullary Syndrome Practical Aspects

Medial Medullary Syndrome: Report of 18 New Patients and a Review of the Literature. Jong Sung Kim, Hyeon Gak Kim, Chin Sang Chung. Stroke. 1995;26:1548-1552
-----------------------
Abstract
Background and Purpose With advanced imaging techniques, infarctions occurring in the medulla are now more easily identified. To date, however, only approximately 30 cases of medial medullary infarction syndrome (MMS) have been reported, and the clinical and radiological characteristics of MMS remain to be studied.
Methods We studied 18 patients (15 men, 3 women; mean age, 62 years) who had compatible clinical and MRI findings of MMS and reviewed the previously reported cases.
Results Seventeen patients had a unilateral lesion usually involving the upper medulla, and 1 had bilateral lesions. Fifteen patients had unilateral sensorimotor stroke, while 2 presented with pure motor stroke. The face was usually but not always spared. The degree of hemiparesis varied, and a tingling sensation with decreased vibration and position sense was the most common sensory manifestation. Two patients had lingual paresis, and none suffered respiratory difficulties. One patient presented with bilateral gait ataxia without sensorimotor dysfunction. Angiography or MR angiography performed in 9 patients showed vertebral artery disease in 6. Three patients had concurrent lateral medullary infarction, and 1 had a previous history of lateral medullary syndrome. The prognosis was generally good, although residual hemiparesis remained in patients with initially severe hemiparesis. Review of 26 previously reported cases showed that they frequently had bilateral lesions, often presenting with quadriplegia, lingual paresis, respiratory symptoms, and a grave prognosis.
Conclusions Our data illustrate that MMS is most often manifested as benign hemisensorimotor stroke frequently associated with tingling sensation and impaired deep sensation. This benign form of MMS should be much more common than MMS with poor prognosis and may have been frequently misdiagnosed as capsular or pontine stroke before the era of MRI. 
----------------------
A few clinical details
Hemiparesis was the most common clinical manifestation of MMS; 15 had contralateral hemiparesis, and 2 (patients 15 and 13) had ipsilateral hemiparesis and crural monoparesis, respectively. One (patient 12) did not have motor weakness but had transient bilateral gait ataxia. In 2 (patients 5 and 14), motor weakness was the only clinical manifestation (pure motor stroke), although patient 5 had slight residual sensory symptoms due to previous LMS. At the peak of the weakness, the degree of the hemiparesis (motor power of the proximal limbs) was severe (0 to 2 on a scale of 5) in 3, moderate (3 on a scale of 5) in 5, and mild (4 or clumsiness on a scale of 5) in 9. Generally, the distal part of the limb (hand and foot) was more severely affected compared with the proximal part. In patients with significant motor deficit, the progression of weakness usually evolved for several hours or days. During this progression, muscle tone was generally flaccid but became spastic during the recovery phase.
Hemisensory symptoms were the second most common clinical manifestation, occurring in 15 patients (including 3 with LMS). Initially, 12 patients felt tingling or a numb sensation. The face was usually spared, but the area of paresthesia occasionally ascended to the periotic area (patients 3 and 11) or even to the midface (patients 9, 16, 17, and 18). Vibration sense was impaired in 14 patients, and decreased position sense was noted in 10. However, only 1 (patient 16) had severely decreased position sense, and none described the vibration sense as reduced more than 50% of the intact side. Seven patients without LMS stated that the pinprick sense was also mildly impaired.
Headache (3 cases) and nausea/vomiting (3 cases) were uncommon, and dizziness/ vertigo was noted in 9 patients. One (patient 18) had transient ipsilateral lingual paresis, and patient 3 showed clumsy tongue movements bilaterally. Including these 2 patients, 4 without LMS had dysarthria, while 2 (patients 2 and 18) had dysphagia. Mild facial paresis was noted in 4 patients. None had respiratory disturbances. One had horizontal nystagmus, 1 had upbeat nystagmus, and 1 had both. Patient 16 had transient gaze paresis and long-lasting sixth nerve palsy.
The patients were followed up for 14 days to 41 months (mean, 11 months). None died during the follow-up period. All were able to walk unassisted, although mild residual paresis remained in patients with initially moderate to severe motor weakness. Uncomfortable paresthesia over the palm or foot became the most distressing symptom in some patients (patients 9, 11, 16, and 17). 
-------------------
Lingual paresis
Unexpectedly, lingual paresis, described in 12 of 26 cases reported in the literature, was observed in only 2 of our patients, with the lesions extending dorsally. Lingual paresis is caused by lesions extending into the lateral part of the medulla, affecting the fibers of the hypoglossal nerves or fascicles, or lesions extending deep into the hypoglossal nucleus.
----------------------------------------
Differences from previous reports
The paucity of lingual paresis and respiratory symptoms along with the patients’ benign outcome was strikingly different from previously described subjects in whom prognosis was generally poor. These differences may be explained in several ways. First and most importantly, the diagnosis of MMS was made by MRI in our patients, whereas that of most of the previously reported cases was based on autopsy. Second, since hypertension seems to be more prevalent and large-vessel atherosclerosis less common in oriental than Western countries, relatively small vessels might have been more often affected in our Korean patients than in previously reported cases. Finally, it may also be possible that the recent progress on risk factor management has led us to encounter more benign cerebrovascular diseases today than before.

Tuesday, July 24, 2012

Movement Disorder Meeting Learning Points

Chennai 22/7/12

  1. Unilateral tongue tremor - PET-CT study of basal ganglionic functions can help
  2. PME's - If valproate is worsening - to consider mitochondrial disorder
  3. Lafora body EEG may show posterior spiking (and giant cortical waveforms on SSEP - stimulus sensitive cortical generators for myoclonus)
  4. Weight gain with valproate would worsen if also given clobazam
  5. Lower limb myoclonus seen in tropical sprue
  6. Lamotrigine described to worsen tics
  7. "End-of-phenotype" - genotype correlations with MRI [discussed by AVS and one more] looked up - the only explanation for the term came from an article - BMC Medical Genetics 2010, 11:114 - Hippocampal and parahippocampal volume reduction is one of the most consistent findings in schizophrenia. Moreover, in a meta-analysis of brain volumes in relatives of patients with schizophrenia, hippocampal reduction was the largest difference between relatives and healthy controls. These findings suggest hippocampal volume as a potential end of phenotype for genetic studies in schizophrenia.
  8. Sea blue histiocytes in generalized dystonia [AVS mentioned] looked up - juvenile dystonic lipidoses with sea blue histiocytes is a variant of Niemann Pick disease type C

Botulinum toxin injection - some practical points

Dr UMS Chennai Workshop on 22/7/12
For Cervical dystonia - torti, lateral, ante, retro
Watch the chin, watch the direction the head takes when the patient is at rest with eyes closed (this will be opposite to the direction where the tremor is maximum), and finally look for asymmetry of muscle hypertrophy. The chin is shifted in torti but not lateralocollis. If torti - needs contralateral SMD + ipsilateral SST complex, if lateral - needs LS, scaleni in addition to trap (?to check for lateral)

Gave inj. to a patient with retro + torti. Identification of SST complex - straight into paraspinal, the toxin will diffuse through to all three muscles. For semispinalis capitis, there is one more inj. point posterior to the insertion of the SMD away from the paraspinal. This is the only muscle here (no overlaps)

For Blepharospasm
Avoid midline (LPS) and give 2 to 3 units at each location, also avoid lower medial canthus (eversion)

For Ankle dorsiflexors (patients with spasticity and toe walking)
Two injections into each head of the gastroc (medial and lateral) and two injections into the middle of the soleus in the center of the bulk

Wednesday, July 18, 2012

Questions regarding seizures

ILAE definition of Seizure:
A seizure is (1) transient (2) occurrence of symptoms and signs (3) due to abnormal enhanced synchronous neuronal activity (4) in the brain

From: Fisher, R. S., Boas, W. v. E., Blume, W., Elger, C., Genton, P., Lee, P. and Engel, J. (2005), Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 46: 470–472. 

Discussion:
(1) It has an onset and termination - transient

(2) Clinical manifestations: Seizure presentation depends on location of onset in the brain, patterns of propagation, maturity of the brain, confounding disease processes, sleep–wake cycle, medications, and a variety of other factors. Seizures can affect sensory, motor, and autonomic function; consciousness; emotional state; memory; cognition; or behavior. Not all seizures affect all of these factors, but all influence at least one. In this context, sensory manifestations are taken to include somatosensory, auditory, visual, olfactory, gustatory, and vestibular senses, and also more complex internal sensations consisting of complex perceptual distortions. In previous definitions, these complex internal sensations were referred to as “psychic” manifestations of seizures.

(3) Hughlings Jackson in 1870 provided a now classic definition of an epileptic seizure as a “symptom … an occasional, an excessive and a disorderly discharge of nerve tissue.” By “disorderly,” Jackson probably meant “capable of producing dysfunction,” which is certainly accurate. However, EEG discharges during epileptic seizures are orderly and relatively stereotyped. Firing of neurons may involve inhibition as well as excitation, so it is not always the case that an epileptic seizure involves an excess of excitation over inhibition. A feature more common to epileptic seizures is abnormal enhanced synchrony of neurons.

(4) Definition of an epileptic seizure becomes operationally difficult without ascribing it to the brain. Trigeminal neuralgia, for example, can result from an abnormal enhanced synchrony of neurons in the trigeminal ganglion or the fifth cranial nerve, but would not be considered an epileptic seizure. Neither would hyperactive spinal reflexes resulting in excessive discharge of anterior horns cells and tonic stiffening of a limb. Cerebral cortex is the primary element in the generation of epileptic seizures, but it is not the only one. In some circumstances, epileptic seizures can originate in thalamocortical interactive systems or in the brainstem.

Some further questions to be answered:
1. Why does it have to be 'transient'? Some seizures are fairly prolonged.

Ans: More than transient, what it really implies is that there is a definite onset (change from baseline) and termination (return to baseline activity). That is, there has to be a beginning and an end to this phenomenon.

2. So, is there a situation where we can have abnormal enhanced synchrony that is present from the time of development of brain (no beginning) or persistent abnormal enhanced synchrony (no end)?

Ans:??


3. Why does the abnormal enhanced synchronous activity occur transiently at certain times in certain brains?

Ans: This assumes that there have to be certain provoking factors (time) with neurons that are susceptible (threshold).

4. What are triggering factors versus provoking factors?

Ans: Some seizures are provoked, that is, they occur in the setting of metabolic derangement, drug or alcohol withdrawal, and acute neurologic disorders such as stroke or encephalitis. Such patients are not considered to have epilepsy, because the presumption is that these seizures would not recur in the absence of the provocation. (from Uptodate)

Triggers: Some patients with epilepsy tend to have seizures under particular conditions, and their first seizure may provide a clue to their so-called seizure trigger. Triggers include (but are not limited to) strong emotions, intense exercise, loud music, and flashing lights. Other physiological conditions such as fever, the menstrual period, lack of sleep, and stress can also precipitate seizures, probably by lowering seizure threshold rather than directly causing a seizure. As a result, the temporal relationship to the presenting seizure is often less clear. Triggers may also precipitate nonepileptic paroxysmal disorders, especially syncope.
However, the majority of patients with epilepsy have no identifiable or consistent trigger to their seizures. In addition, triggers are the sole cause of epileptic seizures in only a very small percentage of patients.

4. So, when do we say that someone has epilepsy?
Ans: We can go back to the article cited above. But generally, epilepsy is characterized by recurrent epileptic seizures due to a genetically determined or acquired brain disorder. Approximately 0.5 to 1 percent of the population has epilepsy.

ILAE definition of Epilepsy:
Epilepsy is (1) a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures (2) and by the neurobiologic, cognitive, psychological, and social consequences of this condition. (3) The definition of epilepsy requires the occurrence of at least one epileptic seizure.

Discussion:
(1) The central concept in the definition of epilepsy is an enduring alteration in the brain that increases the likelihood of future seizures. The diagnosis of epilepsy, under this concept, would not require two seizures; it would require only one epileptic seizure in association with an enduring disturbance of the brain capable of giving rise to other seizures. Multiple epileptic seizures due to multiple different causes in the same patient would not be considered to be epilepsy. A single epileptic seizure due to an enduring epileptogenic abnormality would indicate epilepsy, and a single epileptic seizure in a normal brain would not.

(2) At times, epilepsy must be defined by more than just the recurrence, or a potential for recurrence, of seizures. For some people with epilepsy, behavioral disturbances, such as interictal and postictal cognitive problems, can be part of the epileptic condition. Patients with epilepsy may suffer from stigma, exclusion, restrictions, overprotection, and isolation, which also become part of the epileptic condition. Seizures and the potential for recurrence of seizures also often have psychological consequences for the patient and for the family.

(3) At least one seizure is required to establish the presence of epilepsy; a predisposition, as determined, for example, by a family history, or by the presence of epileptiform EEG changes, is not sufficient to determine epilepsy. The definition does not include a requirement that the seizure be “unprovoked,” a feature of several prior individual definitions. Instead, the definition requires, in addition to at least one seizure, the presence of an enduring alteration in the brain.

Further questions:
1. How do we judge that an individual has "an enduring disturbance of the brain capable of giving rise to further seizures"?

Ans: to be continued....

Friday, July 13, 2012

Zinc treatment in Wilsons as paradigm shift

Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice
Brain Dev. 2006 Apr;28(3):141-6. Epub 2006 Feb 7. 
Hoogenraad TU.
University Department of Neurology, UMC-Utrecht, Heidelberglaan 100, 3584 CX, The Netherlands. tu.hoogenraad@planet.nl

Abstract

Zinc therapy has replaced penicillamine as first-line therapy for Wilson's disease. New guidelines reflect the paradigm shift in treatment that has occurred in recent years. In the old paradigm, Wilson's disease was seen as genetic disorder associated with the accumulation of copper in the liver and in other organs once the liver had become overloaded with copper. When left untreated, the disease was regarded as uniformly fatal. The old treatment guidelines advised, 'decoppering' with penicillamine because this chelating agent was considered effective in restoring most patients to health. Before the start of treatment, patients were warned that their symptoms could worsen during the first weeks or months of therapy, so as to prevent them from abandoning penicillamine therapy in dismay. In the new paradigm, Wilson's disease is seen as a hereditary disorder associated with copper intoxication. The essence of symptomatic Wilson's disease is poisoning by free copper in the blood, that is, by copper that is not bound to ceruloplasmin. This form of copper is toxic, whereas accumulated copper and copper that is bound to ceruloplasmin or metallothionein is not. The treatment of symptomatic Wilson's disease is no longer aimed at 'decoppering', the removal of accumulated copper, but at the normalization of the free copper concentration in blood, to reverse the copper poisoning. This can be achieved safely and effectively with zinc therapy. Zinc induces metallothionein, a highly effective detoxification protein that binds copper. Oral zinc therapy leads to storage of metallothionein-bound copper in the mucosa of the gut and to the excretion of copper via the stools. New treatment guidelines advise against the use of chelating agents as initial treatment because they may aggravate copper intoxication and cause iatrogenic deterioration.

Dorsal Midbrain (Parinaud) syndrome

http://en.wikipedia.org/wiki/Parinaud%27s_syndrome

Parinaud's Syndrome is a cluster of abnormalities of eye movement and pupil dysfunction, characterized by:
  1. Paralysis of upgaze: Downward gaze is usually preserved. This vertical palsy is supranuclear, so doll's head maneuver should elevate the eyes, but eventually all upward gaze mechanisms fail.
  2. Pseudo-Argyll Robertson pupils: Accomodation reflex present, with sluggish/ absent pupillary reflex
  3. Convergence-Retraction nystagmus: Attempts at upward gaze often produce this phenomenon. On fast up-gaze, the eyes pull in and the globes retract. The easiest way to bring out this reaction is to ask the patient to follow down-going stripes on an optokinetic drum.
  4. Eyelid retraction (Collier's sign)
  5. Conjugate down gaze in the primary position: "setting-sun sign".
It is also commonly associated with bilateral papilledema. It has less commonly been associated with spasm of accommodation on attempted upward gaze, pseudoabducens palsy (also known as thalamic esotropia) or slower movements of the abducting eye than the adducting eye during horizontal saccades, see-saw nystagmus and associated ocular motility deficits including skew deviation, oculomotor nerve palsy, trochlear nerve palsy and internuclear ophthalmoplegia.

Dysguesia causes and medicines

Common causes
Orodental infection
Upper respiratory tract infection
Sinus infection

Less common
Idiopathic dysgeusia
Mental illness (e.g. depression)
Drugs

Uncommon
Neurological
Stroke
Head trauma (e.g. fractures of the petrous temporal bone)
Cranial nerve disorders e.g. damage to the chorda tympani during
middle ear surgery
Carotid artery dissection with involvement of the chorda tympani
Facial nerve palsy
Multiple sclerosis
Borrelia burgdorferi associated - neuropathy
Gastrointestinal
Irradiation of the head and neck
Gastrointestinal reflux disease
Hepatitis and hepatic cirrhosis
Malabsorption (e.g. cystic fibrosis)
Crohn’s disease
Others
Diabetes mellitus
Niacin (vitamin B3) deficiency
Zinc deficiency
Copper deficiency
Mercury poisoning

Medications associated with altered taste
Antirheumatic agents Penicillamine, levamisole, gold, levodopa
Antithyroid agents Carbimazole, thiouracil
Anti-inflammatory agents Phenylbutazone, acetylsalicylic acid
Anti diabetic drugs Biguanides
Cytotoxic agents Doxorubicin, methotrexate, vincristine, carmustine
Diuretics and antihypertensive agents Captopril, diazoxide, ethacrynic acid
Antimicrobials Metronidazole, lincomycin, ethambutol, HIV protease inhibitors, Amphotericin
Anti-seizure agents Carbamazepine, baclofen
Others Phenindione, allopurinol, vitamin D, oral contraceptive pill

Saturday, June 16, 2012

Wilsons Ds Penicillamine and Zinc meals relationship

Penicillamine has to be given one hr before or two hr after meals. When giving both Penicillamine and Zinc to the same patient, we can give Penicillamine before meals and Zinc after meals. [Or - give Zinc one hour before meals and Penicillamine two hours after meals]

Friday, March 16, 2012

MRI sensitivity for spinal vascular malformations

The more specific findings of intradural flow voids on T2-weighted images, and/or serpentine enhancement on MRA and T1 images, are seen in 85 to 90 percent of patients.
From: Uptodate

Sensory Neuronopathies

http://neuromuscular.wustl.edu/antibody/sneuron.html

Causes of Sensory Neuronopathies
  1. Immune mediated - paraneoplastic (anti Hu), Sjogren's, acute sensory neuronopathy
  2. Idiopathic - pan-sensory, small fiber, CANVAS
  3. Drugs - Pyridoxine, cisplatin, doxorubicin
  4. Hereditary
  5. Localized - zoster

NB: CANVAS = Cerebellar ataxia, Neuropathy, Vestibular areflexia syndrome

Hereditary Motor Syndromes with Multisystem Involvement

http://neuromuscular.wustl.edu/synmot.html

Hexosaminidase A (Late onset GM2 Gangliosidosis - Tay Sach's disease)
Motor neuropathy +/- CNS (LMN dominant)
Cramps, paresthesias at onset
Symmetric proximal > distal weakness
Fasciculations
+/- CNS involvement - spasticity, ataxia, dementia, dystonia

Adult onset Polyglucosan body disease
CNS + Neuropathy
Dementia in 2/3rd
Cord - spasticity
Nerve - Motor and sensory

Cranial Nerve involvement in CIDP

From Uptodate: 10 to 20% in the classic CIDP

Another cause for myeloneuropathy

Copper deficiency can cause myeloneuropathy. Zinc excess or malabsorption syndrome are the common cause for same. Denture creams containing excess zinc can cause copper deficiency.
In fact zinc is used in Wilson's disease because of its ability to induce metallothionein, which binds copper and reduces its absorption.
Clioquinol, the cause for SMON (myeloneuropathy with optic nerve involvement), is an avid chelator. It has been used in acrodermatitis enteropathica, a childhood disease due to a hereditary defect in zinc transport. Clioquinol binds zinc and improves the transport into the circulation.
From:
Schaumburg H. Copper deficiency myeloneuropathy: A clue to clioquinol-induced subacute myelo-optic neuropathy? Neurology 2008; Vol 71, Issue 9

Dermatomyositis and polymyositis

DM - Humoral immunity directed against vessels, children + adults, CK can be normal
PM - Cytotoxic T cell mediated immune activation against muscle membrane, mostly adults, abnormal CK
Bradley 5th Ed 2008

Tuesday, February 21, 2012

Anemia WHO Cut offs and grading (Wiki)

 WHO's Hemoglobin thresholds used to define anemia  (1 g/dL = 0.6206 mmol/L)
Age or gender group                     Hb threshold (g/dl)      Hb threshold (mmol/l)
Children (0.5–5.0 yrs)                  11.0                            6.8
Children (5–12 yrs)                      11.5                            7.1
Teens (12–15 yrs)                        12.0                            7.4
Women, non-pregnant (>15yrs)    12.0                            7.4
Women, pregnant                         11.0                            6.8
Men (>15yrs)                               13.0                            8.1


WHO Grading of anemia:
  • Grade 1 (Mild Anemia): 10 g/dl - cutoff point for ages
  • Grade 2 (Moderate Anemia): 7-10 g/dl
  • Grade 3 (Severe Anemia): below 7 g/dl

Tuesday, February 14, 2012

SSRI and MAO-BI

SSRI given along with MAO-BI can result in Serotonin syndrome.

Saturday, January 28, 2012

PMP22

Duplication results in HMSN1
Mutation, deletion in HNPP
Done in Delhi SGRH

Tuesday, September 13, 2011

Rasagiline

Selective MAO-B irreversible inhibitor.

Adv over Selegeline - OD dose, milder S/E, non-amphetamine metabolites

ADAGIO trial suggested neuroprotective at 1mg, but findings did not hold at 2mg/day.

Wednesday, September 7, 2011

Knapsack palsy

Typically Long thoracic nerve with serratus anterior palsy

Tuesday, September 6, 2011

Posterior interosseus syndrome

Finger drop without wrist drop (differentiates it from radial palsy due to compression in spiral groove)